ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -12.20% and +3.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?